hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:14:23 - browse：45626

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Google and Epic fight stronger regulation of AI in health care

entertainment

Wikipedia

WSS

How dance can help nurses traumatized by Covid

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Doctors find melanoma drugs effective against rare brain cancer

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Medicare has a new plan to address drug shortages

Sanders adds drug shortage policies to pandemic preparedness bill

focus

hotspot

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

How dance can help nurses traumatized by Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Why hospitals are withdrawing from US News rankings

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Supreme Court strikes down use of affirmative action

A public scorecard can help hold safety

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu: Don't repeat Covid's 'health versus the economy' framing

entertainment

In early work, researchers turn to CRISPR to treat Alzheimer's

Wearables generate powerful data but its not useful to doctors, yet

Cytokinetics CEO stresses company can launch heart drug on its own

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Cosmetics set for new safety regulation. Why the industry is on board

Criminal prosecution for violating HIPAA: an emerging threat

entertainment

knowledge

Wikipedia

Wikipedia